FDA Issues Final Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic

March 23  

Via Faegre Drinker

“On March 18, the U.S. Food and Drug Administration (FDA) issued a final guidance titled FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Pandemic, providing important guidance for industry, investigators and institutional review boards on conducting clinical trials amidst the pandemic. The guidance, finalized without a public consultation period, describes FDA’s recognition of likely disruptions to clinical trials due to the pandemic and acknowledges that deviations from protocols will thus occur. It provides FDA’s current thinking on ways to mitigate the risks posed by these disruptions, focusing on patient safety, good clinical practice and trial integrity. “

“The guidance is applicable to all medical products (human drugs, biologics, and medical devices) undergoing clinical trials, including those being developed to prevent or treat COVID-19, and gives recommendations for both ongoing trials and trials for which procedures are not yet established. In recent days, other agencies have also released guidance on clinical studies impacted by COVID-19, including the National Institutes for Health (NIH) and the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).”

Read the rest of the analysis from Faegre Drinker


The Medical Alley Association is providing COVID-19 related information, including the “COVID-19 Resource Connect” feature on its website and summaries of laws, executive orders, and government programs that may be of interest to members, as a public service.   The Medical Alley Association makes no representations, guarantees, or warranties as to the accuracy, completeness, currency, or suitability of the COVID-19 related information provided by the Medical Alley Association on its website, in newsletters, or in any other communications. The Medical Alley Association specifically disclaims any and all liability for any claims or damages that may result from providing COVID-19 related information online or in other communications or linking to third party websites or other sources of information. The Medical Alley Association makes no effort to independently verify, and does not exert editorial control over, information provided by third parties.  

The Medical Alley Association does not endorse any of the products, vendors, consultants, or documentation referenced in, or connected to parties through, the COVID-19 Resource Connect feature or via this email or other communications.

Success message!
Warning message!
Error message!